VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-13.82%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$1.46B
AUM Growth
+$1.46B
(-24%)
Cap. Flow
-$39.6M
Cap. Flow
% of AUM
-2.72%
Top 10 Holdings %
Top 10 Hldgs %
70.47%
Holding
41
New
3
Increased
5
Reduced
10
Closed
4
Top Buys
| 1 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$37.7M |
| 2 |
Praxis Precision Medicines
PRAX
|
$21.8M |
| 3 |
Cidara Therapeutics
CDTX
|
$20.6M |
| 4 |
enGene Holdings
ENGN
|
$9.85M |
| 5 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$3.88M |
Top Sells
| 1 |
Edgewise Therapeutics
EWTX
|
$26.7M |
| 2 |
Merus
MRUS
|
$13.3M |
| 3 |
Terns Pharmaceuticals
TERN
|
$12.9M |
| 4 |
Arvinas
ARVN
|
$11.2M |
| 5 |
Aquestive Therapeutics
AQST
|
$10.4M |
Sector Composition
| 1 | Healthcare | 99.48% |
| 2 | Financials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $385M | 26.4% | 8,493,321 | – | – |
|
2
Ocular Therapeutix
OCUL
$2.12B
| $109M | 7.48% | 12,762,462 | – | – |
|
3
Enliven Therapeutics
ELVN
$1.2B
| $90.6M | 6.22% | 4,026,331 | – | – |
|
|
4
Praxis Precision Medicines
PRAX
$958M
| $76.2M | 5.23% | 989,985 +283,854 | +40% | +$21.8M |
|
5
Viridian Therapeutics
VRDN
$1.5B
| $74.4M | 5.11% | 3,882,709 | – | – |
|
|
ORKA
6
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $63.7M | 4.37% | 3,285,620 +200,000 | +6% | +$3.88M |
|
7
Spyre Therapeutics
SYRE
$996M
| $62.5M | 4.29% | 2,685,448 | – | – |
|
8
Pharvaris
PHVS
$1.39B
| $61.7M | 4.24% | 3,220,130 -175,476 | -5% | -$3.36M |
|
9
KalVista Pharmaceuticals
KALV
$678M
| $52.9M | 3.63% | 6,249,731 | – | – |
|
10
Dyne Therapeutics
DYN
$1.92B
| $51.2M | 3.51% | 2,173,913 | – | – |
|
11
Cogent Biosciences
COGT
$1.69B
| $44.3M | 3.04% | 5,684,411 +244 | +0% | +$1.9K |
|
12
Erasca
ERAS
$445M
| $40.7M | 2.79% | 16,216,216 | – | – |
|
13
Dianthus Therapeutics
DNTH
$759M
| $38M | 2.61% | 1,744,373 | – | – |
|
|
UPB
14
Upstream Bio, Inc. Common Stock
UPB
$923M
| $37.7M | 2.59% | +2,295,319 | New | +$37.7M |
|
15
Oric Pharmaceuticals
ORIC
$994M
| $35.5M | 2.43% | 4,394,527 | – | – |
|
|
16
enGene Holdings
ENGN
$236M
| $33.6M | 2.3% | 5,046,414 +1,480,573 | +42% | +$9.85M |
|
|
17
Merus
MRUS
$4.98B
| $24.9M | 1.71% | 592,411 -315,552 | -35% | -$13.3M |
|
18
Astria Therapeutics
ATXS
$349M
| $22M | 1.51% | 2,457,348 -1,001,297 | -29% | -$8.95M |
|
|
19
Cidara Therapeutics
CDTX
$1.66B
| $20.6M | 1.41% | +765,723 | New | +$20.6M |
|
20
Cullinan Oncology
CGEM
$445M
| $16.8M | 1.15% | 1,379,965 | – | – |
|
21
4D Molecular Therapeutics
FDMT
$288M
| $16.4M | 1.13% | 2,952,371 -1,447,629 | -33% | -$8.06M |
|
|
ARTV
22
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$76.7M
| $16.2M | 1.11% | 1,609,569 | – | – |
|
23
Mersana Therapeutics
MRSN
$36.5M
| $14.7M | 1.01% | 10,257,790 -1,070,210 | -9% | -$1.53M |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $9.85M | 0.68% | 1,345,780 | – | – |
|
|
25
Aquestive Therapeutics
AQST
$456M
| $9.36M | 0.64% | 2,629,786 -2,925,769 | -53% | -$10.4M |
|